Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer

Core Insights - Astellas Pharma and Vir Biotechnology have entered a global strategic collaboration to co-develop and commercialize VIR-5500, a dual-masked T-cell engager targeting PSMA for prostate cancer treatment [1][2] - The collaboration aims to enhance Astellas' oncology pipeline and leverage both companies' expertise in advancing therapies for prostate cancer [1][2] Financial Terms - Vir Biotechnology will receive $335 million in upfront and near-term milestone payments, including $240 million in cash, $75 million in equity investment at a 50% premium, and a near-term $20 million milestone [1][2] - The companies will share global development costs for VIR-5500, with Astellas covering 60% and Vir Biotechnology 40% [1] - Vir Biotechnology is eligible for up to $1.37 billion in additional development, regulatory, and sales milestones, along with tiered, double-digit royalties on ex-U.S. net sales [1][2] Development and Commercialization - Astellas will lead the commercialization of VIR-5500 in the U.S., while retaining exclusive rights to commercialize the product outside the U.S. [1] - Vir Biotechnology will continue the ongoing Phase 1 trial until responsibility transitions to Astellas, which will then handle all development activities [1][2] - The collaboration is expected to accelerate the advancement of VIR-5500, potentially benefiting more patients with prostate cancer [1][2] Market Context - Prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), remains challenging to treat, with a 5-year survival rate of approximately 30% [1] - VIR-5500 is positioned as a potentially best-in-class treatment option, utilizing PRO-XTEN® masking technology to reduce off-target effects [1][2]